Vincent FERT
-
EVP Immuno-Oncology and EU Operations at Veracyte, Inc.
Veracyte
Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
As an immunologist, I founded HalioDx in 2014 with my former partners at Ipsogen and Jérôme Galon, a world specialist in cancer immunology. In the summer of 2021, HalioDx joined the Veracyte group.
Veracyte implements a radically new approach to cancer diagnosis based on the analysis of the immune response: by precisely measuring the anti-tumour immune response of patients, we enable doctors to determine the severity of the disease, regardless of the cancer stage or molecular profile. Using this measurement, they should also be able to predict the response to treatment of their patients, including immunotherapies, which are at the core of the MI project.
Veracyte (formerly HaliodDx) is a key player in the MI ecosystem that allows both personalized immunotherapies utilization and acceleration of their development.
#industrieHave a look on our testimonies
The thrust of MI is the ability of Marseille researchers, clinicians and industrials to play as a team.
Hervé BRAILLY
Innate Pharma
Unique cluster in the world exclusively dedicated to basic and applied immunology, MI results from an efficient territorial game between research, industry, and the institutional stakeholders in economy and innovation.
Jacques PFISTER
CCI Marseille Provence
For many years our service at the Timone Hospital has collaborated with researchers including the " Natural Killer Cells and Innate Immunity" team of Eric VIVIER .
Nicolas SCHLEINITZ
AP-HM, AMU
Marseille Immunopôle (Marseille Immunology Center) has the potential to provide precious help to open new diagnostic and therapeutic pathways and to provide our patients with even more options.
Pascale TOMASINI
AP-HM, AMU
your commitment to MI